Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review

Forms and Documents

Document Name	Status
pra0389 ss2008.doc Supporting Statement A	2008-08-22

IC Document Collections

IC ID	Document Title	Status
6040	Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review	Modified
186322	Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review	New

ICR Details

OMB Control No: 0910-0389	ICR Reference No: 200808-0910-003
Status: Historical Active	Previous ICR Reference No: 200506-0910-001
Agency/Subagency: HHS/FDA	Agency Tracking No:
Title: Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review
Type of Information Collection: Extension without change of a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 09/29/2008
	Date Received in OIRA: 08/28/2008
Terms of Clearance:

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	09/30/2011	36 Months From Approved	09/30/2008
Responses	137	0	114
Time Burden (Hours)	10,620	0	8,720
Cost Burden (Dollars)	0	0	0

---

Abstract: This guidance is intended to articulate how FDA plans to work with sponsors to achieve expedited development and rapid review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs for the condition. The guidance also meets the requirements of section 112 of the Food and Drug Administration Modernization Act of 1997, which amended the Federal Food, Drug and Cosmetic Act (21 U.S.C. 351 et seq.) by adding new section 506 ("Fast Track Products").

---

Authorizing Statute(s): US Code: 21 USC 301 Name of Law: FFDCA
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	73 FR 25016	05/06/2008
30-day Notice:	Federal Register Citation:	Citation Date:
	73 FR 50028	08/25/2008
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 2

IC Title	Form No.	Form Name
Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review
Guidance for Industry: Fast Track Drug Development Programs - Designation, Development, and Application Review

---

ICR Summary of Burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	137	114	0	0	23	0
Annual Time Burden (Hours)	10,620	8,720	0	0	1,900	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $0

Does this IC contain surveys, censuses, or employ statistical methods? No

Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002? No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? Uncollected

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? Uncollected

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? Uncollected

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 08/28/2008

---